

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

OMB APPROVAL	
OMB Number:	3235-0104
Estimated average burden hours per response:	0.5

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* <u>Antibody Investments LLC</u> (Last) (First) (Middle) 7 HARTOM STREET, 2ND FLOOR, HAR HOTZVIM (Street) JERUSALEM L3 9777507 (City) (State) (Zip)	2. Date of Event Requiring Statement (Month/Day/Year) 08/09/2018	3. Issuer Name and Ticker or Trading Symbol <u>VACCINEX, INC. [VCNX]</u>	
		4. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director <input checked="" type="checkbox"/> 10% Owner Officer (give title below) Other (specify below)	5. If Amendment, Date of Original Filed (Month/Day/Year) 6. Individual or Joint/Group Filing (Check Applicable Line) Form filed by One Reporting Person <input checked="" type="checkbox"/> Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned

1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
---------------------------------	---	--	---

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares			
Series C Convertible Preferred Stock	(1)	(1)	Common Stock	1,346,139	(1)	D	
Series D Convertible Preferred Stock	(2)	(2)	Common Stock	549,444	(2)	D	

1. Name and Address of Reporting Person* <u>Antibody Investments LLC</u> (Last) (First) (Middle) 7 HARTOM STREET, 2ND FLOOR, HAR HOTZVIM (Street) JERUSALEM L3 9777507 (City) (State) (Zip)

1. Name and Address of Reporting Person* <u>Shumacher Michael</u> (Last) (First) (Middle) 7 HARTOM STREET, 2ND FLOOR, HAR HOTZVIM (Street) JERUSALEM L3 9777507 (City) (State) (Zip)
--

Explanation of Responses:

- The reported securities will convert into shares of Common Stock on a 0.1868-for-1 basis immediately prior to the consummation of the Issuer's initial public offering.
- The reported securities will convert into shares of Common Stock on a 1-for-10 basis immediately prior to the consummation of the Issuer's initial public offering.

Remarks:

Michael Shumacher is the sole manager of Antibody Investments LLC. Mr. Shumacher disclaims beneficial ownership of the reported securities except to the extent of his pecuniary interest therein.

ANTIBODY INVESTMENTS
LLC By: /s/ Michael Shumacher, Manager 08/09/2018
/s/ Michael Shumacher 08/09/2018
 ** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).

**** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).**

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.